Anti-Aging peptides

26 peptides tagged anti-aging. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • Acetyl Hexapeptide-3 (Argireline)

    Synthetic acetylated hexapeptide (Ac-EEMQRR-NH2) modelled on the SNAP-25 N-terminus; a 2013 placebo-controlled trial (n=60) found less periorbital wrinkling after 4 weeks of topical use.

    Evidence: Clinical

  • Epithalon

    Synthetic tetrapeptide Ala-Glu-Asp-Gly (PubChem CID 219042); human cell cultures show telomerase induction, and in mice it raised maximum but not mean lifespan.

    Evidence: Preclinical

  • FOXO4-DRI

    Cell-penetrating D-retro-inverso peptide that blocks the FOXO4-p53 interaction, shown in aged mice to selectively kill senescent cells and restore renal function and fitness.

    Evidence: Preclinical

  • GHK Basic

    Copper-free form of the human tripeptide GHK (Gly-His-Lys), studied for collagen synthesis and wound repair, though nearly all published data use the copper complex.

    Evidence: Preclinical

  • GHK-Cu Capsule

    Oral capsule formulation of the copper tripeptide GHK-Cu; oral absorption and systemic efficacy are unestablished, with human evidence limited to topical GHK-Cu.

    Evidence: Anecdotal

  • Glutathione

    Endogenous tripeptide (Glu-Cys-Gly) and the main intracellular antioxidant, central to phase II detoxification and cellular redox defence.

    Evidence: Clinical

  • Humanin

    24-amino-acid peptide encoded within mitochondrial DNA that protected neurons and other cells from oxidative and apoptotic stress in animal and cell studies.

    Evidence: Preclinical

  • Livagen

    Khavinson-series synthetic tetrapeptide (KEDA) designed from liver peptide preparations; studied mainly in cultured lymphocytes from elderly donors and in rat hepatocytes.

    Evidence: Preclinical

  • Matrixyl (Palmitoyl Pentapeptide-4)

    Palmitoylated KTTKS, a fragment of the type I procollagen propeptide, applied topically; a 12-week split-face placebo-controlled trial (n=93) at 3 ppm found fewer fine lines and wrinkles.

    Evidence: Clinical

  • MOTS-c

    Sixteen-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene; shown in animal models to activate AMPK and act as an exercise mimetic improving insulin sensitivity.

    Evidence: Preclinical

  • N-Acetyl Epithalon Amidate

    Acetylated, amidated analog of the pineal tetrapeptide Epitalon (Ala-Glu-Asp-Gly), modified for stability; the parent peptide is studied for telomerase activation and anti-aging effects.

    Evidence: Preclinical

  • NAD+

    Nicotinamide adenine dinucleotide, the central redox coenzyme; a 2026 randomized trial of intravenous NAD+ at 10 mg/day for 7 days raised ejection fraction in 180 ischemic cardiomyopathy patients.

    Evidence: Clinical

  • NMN

    Nicotinamide mononucleotide, a direct oral precursor to NAD+; human trials report raised NAD+ metabolites and improved muscle insulin sensitivity in prediabetic women.

    Evidence: Clinical

  • OS-01

    Topical decapeptide (ETAKHWLKGI-NH2, Peptide 14) from OneSkin that lowered senescence markers in human skin models; two small developer-run RCTs reported better skin barrier function.

    Evidence: Clinical

  • Pal-GHK (Palmitoyl Tripeptide-1)

    Palmitoyl tripeptide-1 (Pal-GHK), a lipidated GHK sold mainly in the Matrixyl 3000 blend; found in human stratum corneum after topical use, with no published single-ingredient efficacy trial.

    Evidence: Preclinical

  • Palmitoyl Dipeptide-6

    Lipidated cosmetic peptide sold under a name whose exact structure could not be confirmed; no peer-reviewed study of any kind was found.

    Evidence: Anecdotal

  • Pentapeptide-18 (Leuphasyl)

    Leucine-enkephalin analog pentapeptide (Tyr-D-Ala-Gly-Phe-Leu) sold as Leuphasyl for expression lines; evidence is manufacturer data, one small emulsion study and in vitro work.

    Evidence: Preclinical

  • Proxofim

    Proprietary FOXO4-DRI-type senolytic peptide sold for research; the parent peptide disrupts FOXO4-p53 binding to kill senescent cells in mice, but this analog itself is unstudied.

    Evidence: Anecdotal

  • Sermorelin

    Synthetic GHRH(1-29) analog (Geref; FDA-approved 1997 for pediatric GH deficiency, withdrawn 2008 for commercial reasons) that restored GH and IGF-1 to young-adult levels in older men (n=10).

    Evidence: Clinical

  • Sermorelin + Ipamorelin Blend

    Vial blend of sermorelin (GHRH 1-29) and ipamorelin, 5 mg each; sermorelin raised GH and IGF-1 in older men, ipamorelin's only RCT was negative, and no study has tested the pair.

    Evidence: Preclinical

  • SNAP-8

    Acetylated octapeptide (Ac-EEMQRRAD-NH2, acetyl octapeptide-3) that extends the Argireline sequence by two residues; human data come only from multi-ingredient products such as microneedle patches.

    Evidence: Preclinical

  • SS-31 (Elamipretide)

    Mitochondria-targeted tetrapeptide that binds cardiolipin. FDA granted accelerated approval on 2025-09-19 as FORZINITY, 40 mg subcutaneously once daily, to improve muscle strength in Barth syndrome.

    Evidence: Clinical

  • Syn-AKE

    Small peptidomimetic (beta-Ala-Pro-Dab benzylamide, sold as the diacetate) modeled on viper waglerin-1; one manufacturer-run RCT (n=57) found less forehead frown-line area at 4 weeks.

    Evidence: Clinical

  • Syn-Coll (Palmitoyl Tripeptide-5)

    Palmitoylated tripeptide (Pal-Lys-Val-Lys) sold as Syn-Coll and marketed as a thrombospondin-1 mimic; evidence is supplier data and multi-ingredient products, with no single-ingredient trial.

    Evidence: Preclinical

  • Tripeptide-29 (Collagen Hexapeptide)

    Collagen-derived tripeptide Gly-Pro-Hyp; it preserved collagen I gene expression in stressed fibroblasts in vitro and oral dosing reduced UV skin damage in mice. No topical study exists.

    Evidence: Preclinical

  • Vialox (Pentapeptide-3V)

    Synthetic pentapeptide amide (Gly-Pro-Arg-Pro-Ala-NH2, pentapeptide-3) marketed as a nicotinic receptor antagonist for expression lines; published data are in silico and cell culture only.

    Evidence: Preclinical

Other categories